WALTHAM, Mass., Oct. 20, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (APLS) today announced that The Lancet published the positive 24-month results from the Phase 3 OAKS and DERBY studies ...

WALTHAM, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from a post hoc analysis of the GALE extension study following five years of ...

SYFOVRE is the only approved GA treatment to demonstrate a visual function benefit in a prespecified endpoint Data presented at the Clinical Trials at the Summit Meeting In a prespecified ...

CHICAGO--(BUSINESS WIRE)--University Retina is proud to be among the first eyecare practices throughout the country to utilize and participate in Apellis Pharmaceuticals’ groundbreaking clinical ...

The Retina Group of New York is offering SYFOVRE™, a revolutionary treatment option for age-related dry macular degeneration (AMD) with geographic atrophy. We are thrilled to offer SYFOVRE to our ...

Five weeks removed from slashing 25% of its workforce amid problems with its groundbreaking geographic atrophy (GA) drug, Apellis is making progress in re-accelerating the launch of Syfovre. Ahead of ...

A Media Snippet accompanying this announcement is available by clicking on this link. WALTHAM, Mass., Nov. 04, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (APLS) today announced data from ...

Jon LaPook, M.D. is the award-winning chief medical correspondent for CBS News. Since joining CBS News in 2006, LaPook has delivered more than 1,200 reports on a wide variety of breaking news and ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye, and it marks the first of a three-part series on dry ...

WAUSAU, Wis. (WSAW) - Geographic atrophy affects approximately one million people in the United States and is commonly associated with both dry and wet macular degeneration. Now a new treatment is ...